Vol. 3, Issue 5

June 2026

Your Quarterly Gateway to Medical Device Trends, Talent, and Transformation

Pulse of Innovation: How Medical Device Leaders Are Navigating Consolidation, Emerging Technologies, and Industry Transformation

In this issue, we explore how the medical device industry is entering a new era shaped by consolidation, technological innovation, and evolving regulatory expectations. Today's market leaders are navigating a landscape where growth depends on more than breakthrough products alone. Success increasingly requires organizations that can integrate acquisitions effectively, accelerate innovation responsibly, and build leadership teams capable of managing complexity at scale. As the industry continues to evolve, medical device companies are redefining what it means to compete, grow, and lead.

Across the industry, major acquisitions are reshaping competitive dynamics while creating new leadership opportunities and succession challenges. Transactions such as Hologic's $18.3 billion go-private, Danaher's $9.9 billion acquisition of Masimo, and Medtronic's continued portfolio expansion are transforming organizations and redefining strategic priorities. At the same time, advances in AI-enabled technologies, software-driven devices, and connected care platforms are increasing demand for leaders who can bridge clinical innovation, regulatory compliance, and commercial execution. The organizations creating the greatest long-term value are those that combine strategic vision with operational discipline and leadership capable of guiding businesses through periods of significant change.

The executives stepping into leadership roles today inherit both extraordinary opportunity and heightened complexity. Whether leading post-acquisition integration, navigating evolving FDA oversight, or scaling next-generation technologies, success increasingly depends on leaders who can operate at the intersection of innovation, execution, and sustainable growth.

Medtech M&A deal value in 2025 — the highest total in over a decade, per PwC

Global medical device market size in 2026, projected to reach $1T+ by 2034

Medtech M&A deals in Q1 2026 alone, totaling $26.6B in value, per J.P. Morgan

INDUSTRY SPOTLIGHT

Medtronic Files to Expand Hugo Surgical Robot Into General Surgery and Gynecology — and Sends a Signal to Every Device Company Watching the Robotics Race

GALWAY, Ireland — Medtronic plc reported fourth quarter and full year fiscal 2026 results on June 3, 2026, delivering its highest annual top-line growth in a decade. Full year revenue reached $36.4 billion, up 8.4% as reported and 5.8% organic, with Q4 revenue of $9.8 billion surpassing guidance by 90 basis points. Cardiac Ablation Solutions led all segments with 78% global growth — including 124% U.S. growth — as the Affera pulsed field ablation platform continued to gain share. The Medical Surgical portfolio grew 5.1% organically, led by double-digit gains in Acute Care & Monitoring.

Alongside the financial results, Medtronic submitted 510(k) filings to expand its Hugo robotic-assisted surgery (RAS) system into general surgery and gynecologic specialties in the U.S., and secured CE Mark for the Stealth AXiS surgical system in spine and cranial indications across Europe. The company also announced its intent to acquire SPR Therapeutics to expand chronic pain management capabilities, and raised its quarterly dividend to $0.72 per share — marking the 49th consecutive year of dividend increases. CEO Geoff Martha cited the results as "the compounding impact of deliberate choices" made to sharpen execution and invest in high-growth platforms including Affera, Symplicity, Hugo, and Stealth AXiS.

Read the Full Announcement

PEOPLE ON THE MOVE

5 Biggest Moves In The Last 90 Days

Johan Folkunger joined Boule Diagnostics as CEO

Boule Diagnostics has appointed Johan Folkunger as CEO, effective June 22, 2026, succeeding Interim CEO Simonetta Tumbiolo. Folkunger brings extensive international leadership experience in healthcare and medtech, including CEO roles at DNV Imatis, SpectraCure, Philips Sweden, and executive leadership at MedCap. The Board cited his strong strategic and operational background as key to leading Boule’s next phase of growth.

View Johan's Profile

Hologic announced today that it named a seasoned medtech veteran as its CEO after closing its go-private acquisition.

Hologic completed its $18.3 billion take-private acquisition by Blackstone and TPG and simultaneously appointed former Baxter CEO José (Joe) Almeida as chief executive officer, succeeding longtime CEO Steve MacMillan upon the deal's close. Almeida's appointment underscores a broader trend across medtech and healthcare companies of pairing major portfolio transformations with experienced operators known for driving strategic focus, operational discipline, and growth. During his tenure at Baxter, Almeida led significant portfolio reshaping initiatives, including major acquisitions and divestitures designed to concentrate resources on higher-growth segments. His appointment at Hologic signals an emphasis on accelerating innovation, strengthening market leadership in women's health, and executing long-term growth strategies under private ownership.

Learn More

Teleflex Appoints Jason Weidman as President and CEO

Teleflex appointed longtime Medtronic executive Jason Weidman as President and CEO, effective June 2026, as the company advances a significant portfolio transformation following multiple divestitures. Weidman, who previously led Medtronic's multi-billion-dollar Coronary & Renal Denervation and Aortic, Peripheral & Venous businesses, was selected to guide Teleflex's next phase of growth focused on interventional, critical care, and high-acuity hospital markets. The appointment reflects a broader trend across the medtech sector of bringing in experienced operating leaders to drive focused growth strategies, accelerate innovation, and unlock value following major portfolio restructuring efforts.

View Jason's Profile

Edwards Lifesciences Announces Appointment of CFO

Edwards Lifesciences appointed Theodora (“Doretta”) Mistras as Chief Financial Officer, effective May 2026, bringing in a seasoned healthcare finance executive from Viatris and a former healthcare investment banker at Citigroup and Goldman Sachs. Mistras succeeds longtime CFO Scott Ullem as Edwards continues executing its differentiated structural heart strategy and investing in innovation-driven growth. The appointment reflects a broader trend across medtech of strengthening executive leadership teams with experienced financial operators who can support strategic capital allocation, M&A evaluation, investor engagement, and long-term value creation as companies navigate increasingly complex growth and innovation cycles.

View Doretta's Profile

Integra reappoints Stuart Essig as CEO

Integra LifeSciences reappointed longtime board chairman and former CEO Stuart Essig as President and Chief Executive Officer, bringing back a proven company veteran to lead the next phase of operational execution and commercial growth. Essig, who previously served as CEO from 1997 to 2012, was tasked with accelerating progress across quality, compliance, operational resilience, and customer-focused transformation initiatives, while the company also elevated commercial leadership through the creation of a new Chief Commercial Officer role. The move reflects a broader trend across medtech of boards turning to experienced insiders with deep institutional knowledge to drive execution, strengthen commercial performance, and navigate complex operational transformations during periods of strategic transition.

View Stuart's Profile

Complete List of C-Level Promotions and Hires in the

Last 90 Days

MEDICAL DEVICE INSIGHTS

Boston Scientific's $14.5B Penumbra Acquisition Signals the M&A Wave Is Far From Over

Boston Scientific and Penumbra announced a definitive agreement on January 15, 2026, valuing Penumbra at approximately $14.5 billion — one of the largest medtech deals of the year. The acquisition gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular, two high-growth vascular segments where it previously had limited presence. CEO Mike Mahoney called it an "opportunity to enter new, fast-growing segments within the vascular space." The deal follows Stryker's $4.9 billion acquisition of Inari Medical in 2025 and signals that consolidation across interventional cardiology, vascular, and neurotech is accelerating — not slowing. Every transaction of this scale creates commercial, clinical, and operational leadership vacancies on both sides of the deal.

Abbott Secures World's First CE Mark for a Dual Glucose-Ketone Sensor — Diabetes Tech Enters a New Era

Abbott announced on May 27, 2026 that it secured CE Mark for the world's first dual glucose-ketone sensing technology for people with diabetes, branded as Libre Duo and Libre Duo 10 Day. The systems continuously measure both glucose and ketone levels every minute in a single wearable sensor — a first-of-its-kind capability designed to detect rising ketones that can rapidly escalate to diabetic ketoacidosis (DKA), a condition responsible for nearly 60% of pediatric Type 1 diabetes hospitalizations in the U.S. Abbott has also filed for FDA clearance. The Libre Duo launch follows Abbott's FY2025 CGM sales of $2 billion — up 15% — and expands the Libre ecosystem to over 8 million users across 60-plus countries. For device talent leaders, the innovation signals a broader shift: diabetes technology companies are moving from glucose management into full metabolic monitoring platforms, demanding a new generation of commercial, clinical, and market access leaders who can build and scale categories that do not yet have established reimbursement pathways in the U.S.

FDA's New QMSR Took Effect February 2 — the Biggest Quality System Overhaul in a Generation

The FDA's Quality Management System Regulation (QMSR) became effective on February 2, 2026, replacing the decades-old Quality System Regulation (QSR) under 21 CFR Part 820 and incorporating ISO 13485:2016 by reference. The FDA simultaneously retired its Quality System Inspection Technique (QSIT) and launched a new inspection compliance program (CP 7382.850). Manufacturers that had not yet aligned their quality systems with ISO 13485 are now subject to a fundamentally different inspection approach — one that extends FDA scrutiny to management review, quality audits, and supplier audit reports that were previously shielded. For talent advisors, the transition is driving immediate demand for regulatory affairs and quality leaders who understand both FDA enforcement and international ISO compliance frameworks simultaneously.

Spotlight Contributor

Bernard Layton

Talent Pulse Partners, Co-Founder

Bernard Layton is a seasoned executive search leader with more than 35 years of experience helping organizations align leadership talent with business-critical outcomes.

Throughout his career, Bernard has worked closely with boards, investors, and executive teams across highly regulated and complex industries, developing a deep understanding of how the right leadership expertise, at the right time, can materially impact performance, risk management, and growth. As healthcare and clinical service organizations faced increasing pressure to move faster without taking on long-term overhead, Bernard recognized a growing gap between traditional hiring models and the need for immediate, specialized leadership.

Over the past 15+ years, Bernard has been an innovator in talent intelligence and search infrastructure, designing proprietary CRM and data systems to support rigorous market mapping, long-term relationship management, and strategic talent deployment. This work culminated in KeyHires, a purpose-built platform that enables scalable access to deeply vetted leadership talent.

Talent Pulse Partners was created as a natural extension of this foundation—bringing fractional leadership to organizations that need senior clinical expertise without the cost, uncertainty, or extended timelines of full-time hiring.

Bernard’s work is grounded in the belief that exceptional outcomes, especially in healthcare, are driven by aligning the right expertise with the right mission, exactly when it is needed most.

More Information

Connect On LinkedIn

Questions? Ask Away!

;

— STAY AHEAD

Don't miss the next issue

Be at the forefront of the digital healthcare revolution. We provide you with insights on trends, talent management, and executive leadership — delivered with the depth your organization deserves.

This newsletter is sponsored by Talent Pulse Partners. At Talent Pulse Partners, we specialize in connecting organizations with exceptional executive talent that propels growth and success. In today's competitive landscape, the right leadership can make all the difference. Our team of experienced recruiters are dedicated to finding top-tier executives who possess the skills, vision, and expertise to drive your business forward.

Don't miss out on the opportunity to secure the top talent your company deserves. Contact Bernard Layton, leader of our digital health practice, at blayton@talentpp.com to learn more about how Talent Pulse Partners can help you find the exceptional leaders who will transform your organization.